Kritikos Alexandra F, Taylor Bruce, Lamuda Phoebe, Pollack Harold, Schneider John A
NORC at the University of Chicago, Cambridge Innovation Center, 1 Broadway, Cambridge, MA 02142, United States.
NORC at the University of Chicago, 55 E Monroe St., 30th Floor, Chicago, IL 60603, United States.
Drug Alcohol Depend. 2025 Jul 1;272:112680. doi: 10.1016/j.drugalcdep.2025.112680. Epub 2025 Apr 22.
As cannabis usage continues to surge in the United States, understanding the nuances between medical and recreational use, as well as the frequency of past-month consumption, is critical for public health. The need to differentiate these patterns and assess their implications for Cannabis Use Disorder (CUD) is important for both clinical care and health policy in the United States.
This study utilized data from the AmeriSpeak® web-based panel, a nationally representative sample of U.S. households. Participants (n = 1719) were adults aged 18 and older who completed a self-report survey in December 2023 or January 2024 and reported past-month cannabis use. The Cannabis Use Disorder Identification Test (CUDIT) was employed to measure usage frequency and identify CUD risk, with scores of 8 or more indicating hazardous use and scores of 12 or more indicating possible CUD. Multinomial logistic regressions were conducted to explore associations between sociodemographic characteristics and cannabis dependence, further segmented by past-month frequency of medical and recreational use.
Approximately 10 % of adults reported past-month medical cannabis use and 17 % reported recreational use. Any past-month medical cannabis use was associated with a 26 % CUD rate (95 % CI: 19.8-30.4) and hazardous use rate of 25 % (95 % CI: 18.5-31.2). When broken down by frequency, CUD rates ranged from 16 % to 34 % for people who use cannabis for medical purposes : occasional use (19 %, 95 % CI: 13.7-24.3), moderate use (24 %, 95 % CI: 17.5-30.5), and daily or near-daily use (31 %, 95 % CI: 24.1-38.3). People who use cannabis for non-medical (recreational) reasons showed a 21 % overall CUD rate (95 % CI: 17.7-25.2), with segmented rates by frequency indicating 10 % for occasional use (95 % CI: 6.2-13.8), 24 % for moderate use (95 % CI: 18.1-29.9), and 32 % for daily or near-daily use (95 % CI: 25.3-38.7). Younger adults (18-29) and males were identified as the most at-risk groups, exhibiting the highest CUD scores across both medical and recreational categories.
Over a quarter of people who use cannabis meet the criteria for CUD, underscoring the importance of more precise assessments of cannabis use patterns. While no significant differences between medical and recreational cannabis use were observed, the nuances in usage patterns become obscured when grouping all individuals who use cannabis in the past-month together, potentially masking important differences in risk levels. Integrating frequency and quantity metrics into clinical assessments, similar to practices in alcohol consumption research, is imperative. This approach allows healthcare providers to gain a comprehensive understanding of cannabis use behaviors and associated CUD risks, providing crucial insights for developing targeted interventions, support services, and strategies to address cannabis-related health risks effectively.
随着大麻在美国的使用量持续飙升,了解医疗用途和娱乐用途之间的细微差别以及过去一个月的消费频率,对公共卫生至关重要。区分这些模式并评估其对大麻使用障碍(CUD)的影响,对美国的临床护理和卫生政策都很重要。
本研究使用了来自AmeriSpeak®基于网络的面板数据,这是一个具有全国代表性的美国家庭样本。参与者(n = 1719)为18岁及以上的成年人,他们在2023年12月或2024年1月完成了一份自我报告调查,并报告了过去一个月的大麻使用情况。采用大麻使用障碍识别测试(CUDIT)来测量使用频率并识别CUD风险,得分8分及以上表明使用危险,得分12分及以上表明可能患有CUD。进行多项逻辑回归以探索社会人口学特征与大麻依赖之间的关联,并按过去一个月医疗和娱乐用途的频率进一步细分。
约10%的成年人报告过去一个月使用过医用大麻,17%报告有娱乐用途。过去一个月内任何医用大麻使用与26%的CUD发生率(95%置信区间:19.8 - 30.4)和25%的危险使用率(95%置信区间:18.5 - 31.2)相关。按频率细分时,医疗用途大麻使用者的CUD发生率在16%至34%之间:偶尔使用(19%,95%置信区间:13.7 - 24.3)、适度使用(24%,95%置信区间:17.5 - 30.5)以及每日或近乎每日使用(31%,95%置信区间:24.1 - 38.3)。非医疗(娱乐)用途大麻使用者的总体CUD发生率为21%(95%置信区间:17.7 - 25.2),按频率细分的发生率为偶尔使用10%(95%置信区间:6.2 - 13.8)、适度使用24%(95%置信区间:18.1 - 29.9)以及每日或近乎每日使用32%(95%置信区间:25.3 - 38.7)。较年轻的成年人(18 - 29岁)和男性被确定为风险最高的群体,在医疗和娱乐类别中均表现出最高的CUD得分。
超过四分之一的大麻使用者符合CUD标准,这凸显了更精确评估大麻使用模式的重要性。虽然未观察到医用和娱乐用大麻使用之间的显著差异,但将过去一个月内所有使用大麻的个体归为一组时,使用模式的细微差别变得模糊,可能掩盖了风险水平的重要差异。将频率和数量指标纳入临床评估,类似于酒精消费研究中的做法,势在必行。这种方法使医疗保健提供者能够全面了解大麻使用行为及相关的CUD风险,为制定针对性干预措施、支持服务以及有效应对大麻相关健康风险的策略提供关键见解。